Keyphrases
Evidence-based Review
100%
Ustekinumab
100%
Psoriasis Treatment
100%
Psoriasis
42%
Moderate-to-severe Psoriasis
42%
Interleukin-23 (IL-23)
28%
Rapid Onset
28%
T Helper 17 (Th17)
28%
Onset of Action
28%
Monoclonal Antibody
14%
Therapeutic Potential
14%
T Cells
14%
Clinical Improvement
14%
Current Therapeutics
14%
Complex Disease
14%
Placebo
14%
Phase II Trial
14%
T Helper Cells
14%
Autoimmune
14%
Interleukin-12 (IL-12)
14%
Quality of Life Assessment
14%
Clinical Potential
14%
Severity Index
14%
T-cell Mediated
14%
Dosing Schedule
14%
Safety Profile
14%
Novel Agents
14%
Evidence Review
14%
Chronic Inflammatory Skin Disease
14%
Armamentarium
14%
Subcutaneous Injection
14%
Psoriasis Area
14%
Area Index
14%
Psoriasis Severity
14%
Interleukin-22 (IL-22)
14%
Physician Global Assessment
14%
3 to 5 Years
14%
Efficacy Profile
14%
Treatment Alternatives
14%
Assessment Score
14%
Phoenix
14%
Psoriatic Patients
14%
IL Interleukin
14%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
100%
Ustekinumab
100%
Interleukin 23
28%
Disease
28%
Cytokine
14%
Tumor Necrosis Factor
14%
Placebo
14%
Dermatitis
14%
Human Monoclonal Antibody
14%
Psoriasis Vulgaris
14%
Subcutaneous Injection
14%
Immunology and Microbiology
Ustekinumab
100%
Interleukin 23
28%
T Cell
28%
T Helper Cell
14%
Tumor Necrosis Factor
14%
Arm
14%
Human Monoclonal Antibody
14%
Cytokine
14%
Dermatitis
14%